



November 13, 2012

## **Orthofix Announces International Launch of TrueLok™ Hexapod System and Extended Partnership with TSRHC**

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today the launch of the TrueLok™ Hexapod System, or TL-HEX, through its international orthopedic distribution network. This external hexapod ring-type fixator for deformity correction and complex trauma treatment represents the next step in the evolution of the Company's TrueLok™ circular fixation platform. The multipolar System together with the associated software provides access to the largest segment of the circular and hybrid fixation markets that are dominated by one product.

TL-HEX and its software were co-developed with the Company's partner Texas Scottish Rite Hospital for Children (TSRHC). This partnership was recently extended through 2028 and has yielded one of Orthofix's most successful orthopedic products.

President and Chief Executive Officer Robert Vaters said, "As a global leader in external fixation, Orthofix is very excited to initiate its international launch of TL-HEX, which truly improves the lives of patients who are suffering from orthopedic deformities or from trauma. With our partners at the Texas Scottish Rite Hospital for Children, we stay committed to the research and development of future ground breaking external fixation technology."

The first surgery was performed by Dr. Franz F Birkholtz in South Africa in November.

The TrueLok™ Hexapod System is planned to launch during the fourth quarter 2012 in certain international markets and is on display this week at the annual meetings of the Italian Society of Orthopaedics and Traumatology (SIOT) in Rome, Italy and the French Society of Orthopedic Surgery and Traumatology (SOFOT) in Paris, France.

### **About Orthofix:**

Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix's products are widely distributed around the world to orthopedic surgeons and patients via Orthofix's sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit [www.orthofix.com](http://www.orthofix.com).

### **About Texas Scottish Rite Hospital for Children:**

Texas Scottish Rite Hospital for Children is one of the nation's leading pediatric centers for the treatment of orthopedic conditions, certain related neurological disorders and learning disorders, such as dyslexia. Admission is open to Texas children from birth up to 18 years of age. Patients receive treatment regardless of the family's ability to pay. For more information, to volunteer or to make a donation, please call (214) 559-5000 or (800) 421-1121 or visit [www.tsrhc.org](http://www.tsrhc.org).

Orthofix International N.V.  
Mark Quick, 214-937-2924  
Director of Investor Relations and Business Development  
[markquick@orthofix.com](mailto:markquick@orthofix.com)

Source: Orthofix International N.V.

News Provided by Acquire Media